

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)

**COMPLETION OF FULL REDEMPTION AND WITHDRAWAL OF
LISTING OF THE US\$300 MILLION ZERO COUPON
CONVERTIBLE BONDS DUE 2024
(Debt Stock Code: 6015)**

Reference is made to the announcements of WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”) dated September 3, 2019, September 4, 2019, September 5, 2019, September 17, 2019, June 3, 2020, June 7, 2021 and March 15, 2023 (the “**Announcements**”) in relation to, among other things, the issue of the US\$300 million zero coupon convertible bonds due 2024 (the “**Bonds**”) and the final reminder on early redemption of the Bonds. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements.

The Company hereby announces that it has exercised its option to redeem all the outstanding Bonds in full on April 4, 2023 at the price of U.S.\$104,519.38 for each U.S.\$100,000 principal amount in accordance with the terms and conditions of the Bonds. Accordingly, there are no outstanding Bonds in issue following the abovementioned redemption as at the date of this announcement. The Company has applied to the Stock Exchange for the withdrawal of the listing of the Bonds. Such withdrawal of listing is expected to become effective upon the closure of business on April 17, 2023.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, April 4, 2023

As at the date of this announcement, the Board comprises Dr. Ge Li, Mr. Edward Hu, Dr. Steve Qing Yang, Dr. Minzhang Chen, Mr. Zhaohui Zhang and Dr. Ning Zhao as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Dr. Jiangnan Cai, Ms. Yan Liu, Dr. Hetong Lou, Mr. Xiaotong Zhang and Mr. Dai Feng as independent non-executive Directors.

* For identification purposes only